1 / 21

再生障碍性贫血 免疫发病机制 的探讨

再生障碍性贫血 免疫发病机制 的探讨. 中山大学附属第三医院血液科 胡 婷 硕士研究生. Definition. 再生障碍性贫血 ( Aplastic anemia ) acquired aplastic anemia Bone marrow failure syndromes is characterized by peripheral blood cytopenia and reduced marrow cellularity. seed. soil. bug. 造血干祖细胞缺陷(质和量的异常). 造血微环境异常. 免疫异常. 传统观点.

Download Presentation

再生障碍性贫血 免疫发病机制 的探讨

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 再生障碍性贫血免疫发病机制的探讨 中山大学附属第三医院血液科 胡 婷 硕士研究生

  2. Definition 再生障碍性贫血(Aplastic anemia) • acquired aplastic anemia • Bone marrow failure syndromes • is characterized by peripheral blood cytopenia and reduced marrow cellularity.

  3. seed soil bug 造血干祖细胞缺陷(质和量的异常) 造血微环境异常 免疫异常 传统观点

  4. Which comes first? Q Whether there is a causal relationship between the two ? Q Question

  5. Therapy 造血干细胞移植 40岁以下 无感染及其它 并发症 有合适供体的 SAA患者 免疫抑制治疗 抗淋巴/胸腺细胞 球蛋白 环孢素等 促造血治疗 雄激素 造血生长因子

  6. Hot topic 细胞免疫异常是AA的主要发病机制

  7. T 细胞介导的免疫抑制 1 淋巴因子的免疫作用 2 Content

  8. T细胞介导的免疫抑制 TCR – Vβ的CDR3为T细胞克隆的区分标志,AA患者曲线出现数个寡克隆峰。 以CD28为激活的T细胞分选标记, 这群细胞中CDR3优势克隆比例尤其高。 Invivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing.Lancet. 2004

  9. T细胞介导的免疫抑制 • T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood. 2006 Itk PKCθ T-bet IFN-γ Th1细胞激活和扩增 Th1型T细胞反应 干细胞损伤

  10. T细胞介导的免疫抑制 • Increased CD4+ and CD8+ effector memory T cells in patients with aplastic anemia. Haematologica, 2009 (IF5.5) AA患者CD45RA-CCR7-效应T记忆细胞增多 更快更强更有效的免疫应答

  11. T细胞介导的免疫抑制 • Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood. 2007 NFAT1和FOXP3表达水平低 CD4+CD25+FOXP3+调节性T细胞缺陷 与自身免疫性疾病类似

  12. 细胞因子的免疫作用 • 细胞因子的造血负调控作用 造血负调控因子: 白细胞介素-2(IL-2) -干扰素(IFN-) 肿瘤坏死因子-(TNF-)

  13. 细胞因子的免疫作用 • Anti-moesin antibodies in the serum of patients with aplastic anemia stimulate peripheral blood mononuclear cells to secrete TNF-alpha and IFN-gamma. J Immunol ,2009 (IF6.0) 抗膜突蛋白抗体 AA 分泌TNFα和IFNγ 间接抑制 AA骨髓造血

  14. 细胞因子的免疫作用 • 负调控因子的作用机制 • Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia。J Immunol. 2002 IFN - γ和TNF –α 造血干细胞 p38 MAPKK2细胞凋亡

  15. 细胞因子的免疫作用 • Increased inducible nitric oxide synthase expression and nitric oxide concentration in patients with aplastic anemia. Ann Hematol. 2003 IFNγ IRF-1 iNOS NO DNA损伤与细胞凋亡

  16. Reference • Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006 • Aplastic anemia: pathogenesis and treatment.Hematology Am Soc Hematol Educ Program.2007

  17. Reference • Perforin gene mutations in patients with acquired aplastic anemia.blood.2007 • Lymphocytes with aberrant expression of Fas or Fas ligand attenuate immune bone marrow failure in a mouse model. JImmunol. 2009

  18. 存在的问题 基础与临床的结合? 至今也没有按发病机制或病理生理学进行再障分类的建议; 众多的再障免疫异常指标能用于判断疗效和转归者也少。

  19. 无论是重型或非重型再障都有约1/3的患者免疫抑制治疗无效 免疫发病机制仍有许多疑点

  20. Thank You !

More Related